Literature DB >> 1501780

Increase of plasma neuropeptide Y-like immunoreactivity following chronic hypoxia in the rat.

J T Cheng1, C F Chen, A Y Shum, J Y Wang, H I Chen.   

Abstract

In an attempt to understand the changes of circulating neuropeptide Y (NPY) during hypoxia, the plasma level of NPY was investigated by radioimmunoassay. Exposure of rats to hypobaric hypoxia at an altitude of 18,000 ft for 4 weeks causes an increase of pulmonary pressure and an elevation of plasma NPY-like immunoreactivity (NPY-LI). However, the systemic blood pressure was not elevated by this chronic hypoxia. Also, plasma noradrenaline (NA) estimated by chromatographic analysis (HPLC-ECD) was not markedly raised. Failure of bretylium and guanethidine, sympathetic neuron blockers, in reducing the plasma NPY-LI level of these rats ruled out the participation of adrenergic nervous terminals. Adrenal medulla seems responsible for this elevation of plasma NPY-LI because this magnitude disappeared in adrenalectomized rats. These data suggest that chronic hypoxia induced an elevation of circulating NPY from the adrenal gland of rats.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1501780     DOI: 10.1016/0304-3940(92)90105-g

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  2 in total

1.  Lack of association between impaired glucose tolerance and appetite regulating hormones in patients with obstructive sleep apnea.

Authors:  Ioannis Papaioannou; Michael Patterson; Gillian L Twigg; Ali Vazir; Mohammad Ghatei; Mary J Morrell; Michael I Polkey
Journal:  J Clin Sleep Med       Date:  2011-10-15       Impact factor: 4.062

2.  The role of neuropeptide Y in the ovine fetal cardiovascular response to reduced oxygenation.

Authors:  Emilia M Sanhueza; Anja A Johansen-Bibby; Andrew J W Fletcher; Raquel A Riquelme; Alejandro J Daniels; Maria Serón-Ferré; Cristián R Gaete; Jorge E Carrasco; Aníbal J Llanos; Dino A Giussani
Journal:  J Physiol       Date:  2003-02-01       Impact factor: 5.182

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.